Home > Press > Mark Davis to moderate 'Novel approaches to drug delivery in cancer' session at the AACR meeting
Founder of Insert Therapeutics and Calando Pharmaceuticals Sheds Light on Nanoparticle Therapeutics for Cancer
Mark Davis to moderate 'Novel approaches to drug delivery in cancer' session at the AACR meeting
PASADENA, CA, | Posted on April 12th, 2007
Arrowhead Research Corporation (NASDAQ:ARWR) announced today that Mark Davis, Ph.D, the founder of two of its majority-owned subsidiary companies Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. will moderate and speak at the "Novel Approaches to Drug Delivery in Cancer" session during the 2007 American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 14, 2007. This session will also feature Dr. Dong Shin (Winship Cancer Center), Dr. Peter Senter (Seattle Genetics) and Dr. Anna Wu (UCLA).
In his role as a speaker, Dr. Davis will deliver a presentation
titled "Fundamental Issues in Nanoparticle Therapeutics for Cancer"
in which he will review such critical factors as control of size and
surface charge of nanoparticles. In addition, he will explain the
features of nanoparticles that make them particularly interesting for
cancer therapeutics, such as multivalent targeting to cell surface
receptors. Dr. Davis will also describe a nanoparticle experimental
therapeutic that is in early clinical trials.
"The session is predicated on the increasing necessity to overcome
existing limitations in drug delivery systems for cancer," said Dr.
Davis. "We aim to summarize some of the most exciting new
technologies in the pre-clinical and clinical settings with emphasis
on their role in providing better approaches to drug delivery."
In addition to being the Founder of Insert Therapeutics and Calando
Pharmaceuticals, Dr. Davis is the Warren and Katharine Schlinger
Professor of Chemical Engineering at the California Institute of
Technology. He is a member of the National Academy of Engineering and
the National Academy of Sciences, and a recipient of numerous awards
including the prestigious Alan T. Waterman Award, given by the
National Science Foundation annually to only one scientist in the
United States across all disciplines. Dr. Davis was the first
engineer to win this award for his work in rationally designed
materials. Dr. Davis earned his B.S., M.S. and Ph.D. degrees in
Chemical Engineering and holds over 50 patents, has published more
than 350 papers and has presented over 500 seminars throughout the
About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a
publicly-traded nanotechnology company commercializing new
technologies in the areas of life sciences, electronics, and energy.
Arrowhead is building value for shareholders through the progress of
majority owned subsidiaries founded on nanotechnologies originally
developed at universities. The company works closely with
universities to source early stage deals and to generate rights to
intellectual property covering promising new nanotechnologies.
Currently, Arrowhead has four subsidiaries commercializing nanotech
products and applications, including anti-cancer drugs, RNAi
therapeutics, carbon-based electronics and compound semiconductor
About Insert Therapeutics, Inc.
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead
Research Corporation (NASDAQ:ARWR), is using its proprietary,
nano-engineered, polymeric delivery system, Cyclosert(TM), to design,
develop and commercialize drug-delivery-enhanced small-molecule
therapeutics and nucleic acids. Cyclosert uses cyclodextrins as
building blocks to create an entirely new class of biocompatible
materials - linear cyclodextrin-containing polymers that are nontoxic
and nonimmunogenic at therapeutic doses. Insert is pursuing this goal
through its internal research and development and also through
collaborations and partnerships with pharmaceutical and biotechnology
About Calando Pharmaceuticals Inc.
Calando Pharmaceuticals Inc., a majority owned subsidiary of
Arrowhead Research Corporation (NASDAQ: ARWR), is using its
proprietary technologies in targeted polymeric delivery systems and
siRNA design to design and create new, targeted siRNA therapeutics.
The company is pursuing this goal through its internal research and
development and also through collaborations and partnerships with
pharmaceutical and biotechnology companies.
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
This news release contains forward-looking statements within the
meaning ofthe "safe harbor" provisions of the Private Securities
Litigation Reform Actof 1995. These statements are based upon our
current expectations and speak onlyas of the date hereof. Our actual
results may differ materially and adversely from those expressed in
any forward-looking statements as a result of various factorsand
uncertainties, including the recent economic slowdown affecting
technology companies, the future success of our scientific studies,
our ability to successfully develop products, rapid technological
change in our markets, changes in demand for our future products,
legislative, regulatory and competitive developments and general
economic conditions. Our Annual Report on Form 10-K and 10-K/A,
recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A,
recent Current Reports on Forms 8-K and 8-K/A, our Registration
Statement on Form S-3, and other SEC filingsdiscuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We undertake no obligation to
revise or update publicly any forward-looking statements for any
For more information, please click here
Copyright © Arrowhead Research Corporation
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nanoscale assembly line August 29th, 2014
Copper shines as flexible conductor August 29th, 2014
Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices August 28th, 2014
PetLife Comments on CNN Story on Scorpion Venom Health Benefits August 27th, 2014
A new, tunable device for spintronics: An international team of scientists including physicist Jairo Sinova from the University of Mainz realises a tunable spin-charge converter made of GaAs August 29th, 2014
Nanoscale assembly line August 29th, 2014
New analytical technology reveals 'nanomechanical' surface traits August 29th, 2014
New Vice President Takes Helm at CNSE CMOST: Catherine Gilbert To Lead CNSE Children’s Museum of Science and Technology Through Expansion And Relocation August 29th, 2014
SouthWest NanoTechnologies CEO Dave Arthur to Discuss “Carbon Nanotubes and Automotive Applications” at The Automotive Composites Conference and Expo 2014 (ACCE2014) August 28th, 2014
Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014
Malvern specialists to deliver inaugural short course on polymer characterization at Interplas 2014 August 27th, 2014
Wyatt Technology’s 24th International Light Scattering Colloquium to Highlight Developments in Applications and Characterization of Nanoparticles August 21st, 2014